85-1451-29 [取扱停止]Lanreotide 1mg L1275
特徴
- Lanreotide is a peptide inhibitor of a number of endocrine, neuroendocrine, exocrine and paracrine functions. It shows good affinity for peripheral somatostatin receptors (anterior pituitary and pancreatic). In contrast, its affinity for central receptors is much lower. This profile confers a good specificity of action at the level of growth hormone and digestive hormone secretion. Lanreotide shows a much longer duration of action than natural somatostatin. In addition, its marked selectivity for the secretion of growth hormone, compared to that of insulin, makes it a suitable candidate for the treatment of acromegaly. By inhibiting the synthesis of thyroid stimulating hormone (TSH), lanreotide also normalised thyroid function of patients with thyrotrophin secreting adenomas in 50% (8/16) of the per-protocol population treated for 6 months. There was no significant reduction in the size of the adenoma. Furthermore, the inhibitory action of lanreotide on intestinal exocrine secretion, digestive hormones and cellular proliferation mechanisms is suited to the symptomatic treatment of endocrine digestive tumors, especially carcinoids. Lanreotide is an octapeptide, an analogue of a naturally occurring hormone, somatostatin. Lanreotide lowers the levels of hormones in the body such as GH (growth hormone) and IGF-1 (insulin-like growth factor-1) and inhibits some digestive hormones and intestinal secretions.
- Dimers and Aggregates:Less than 1% as determined by silver-stained SDS-PAGE gel analysis.
- Endotoxin:≤ 0.1ng/ug (IEU/ug) of Lanreotide.
- Solubility:It is recommended to reconstitute the lyophilized Lanreotide in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
- Stability:Lyophilized Lanreotide although stable at room temperature for 3 weeks, should be stored desiccated below -180C. Upon reconstitution Lanreotide should be stored at 40C between 2-7 days and for future use below -180C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.
仕様
- Size:1mg
- Grade:Highly Purified
- Purity:≥ 99% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.
- Form:Supplied as a lyophilized powder with 5mg manntitol and 0.04mg Tween 80.
- EU Commodity Code:38220090
- この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
- 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
- 【試薬に関するお問合せ】
- アズワン株式会社 試薬・プロセス材料グループ
- TEL:06-6447-8641
- FAX:06-6447-8642
- E-mail:[email protected]
商品のバリエーション (サイズ違い・スペック違い・オプション品など)
| 商品イメージ | アズワン品番 商品名 |
|---|---|
|
85-1451-29
Lanreotide 1mg
|
|
|
85-1451-28
Lanreotide 200ug
|
よくあるご質問(FAQ)
掲載カタログ情報
| 掲載カタログ名 | 掲載ページ |
|---|





